These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10657986)

  • 1. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
    Yoon SS; Nakamura H; Carroll NM; Bode BP; Chiocca EA; Tanabe KK
    FASEB J; 2000 Feb; 14(2):301-11. PubMed ID: 10657986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
    Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
    Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
    Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus.
    Carroll NM; Chiocca EA; Takahashi K; Tanabe KK
    Ann Surg; 1996 Sep; 224(3):323-9; discussion 329-30. PubMed ID: 8813260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector.
    Yoon SS; Carroll NM; Chiocca EA; Tanabe KK
    Ann Surg; 1998 Sep; 228(3):366-74. PubMed ID: 9742919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus.
    Pawlik TM; Nakamura H; Yoon SS; Mullen JT; Chandrasekhar S; Chiocca EA; Tanabe KK
    Cancer Res; 2000 Jun; 60(11):2790-5. PubMed ID: 10850415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses.
    Kimata H; Takakuwa H; Goshima F; Teshigahara O; Nakao A; Kurata T; Sata T; Nishiyama Y
    Hepatogastroenterology; 2003; 50(52):961-6. PubMed ID: 12845959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.
    Nakamura H; Mullen JT; Chandrasekhar S; Pawlik TM; Yoon SS; Tanabe KK
    Cancer Res; 2001 Jul; 61(14):5447-52. PubMed ID: 11454690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
    Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
    Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.
    Nakamura H; Kasuya H; Mullen JT; Yoon SS; Pawlik TM; Chandrasekhar S; Donahue JM; Chiocca EA; Chung RY; Tanabe KK
    J Clin Invest; 2002 Apr; 109(7):871-82. PubMed ID: 11927614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.
    Wildner O; Morris JC
    J Gene Med; 2000; 2(5):353-60. PubMed ID: 11045429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
    Mullen JT; Donahue JM; Chandrasekhar S; Yoon SS; Liu W; Ellis LM; Nakamura H; Kasuya H; Pawlik TM; Tanabe KK
    Cancer; 2004 Aug; 101(4):869-77. PubMed ID: 15305421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
    Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer.
    Argnani R; Marconi P; Volpi I; Bolanos E; Carro E; Ried C; Santamaria E; Pourchet A; Epstein AL; Brocker T; Corrales FJ; Manservigi R; Goicoechea I; Foschini M; Hernandez-Alcoceba R
    Liver Int; 2011 Nov; 31(10):1542-53. PubMed ID: 22093330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
    Wildner O; Morris JC
    Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.
    Wakimoto H; Johnson PR; Knipe DM; Chiocca EA
    Gene Ther; 2003 Jun; 10(11):983-90. PubMed ID: 12756419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
    Fu X; Zhang X
    Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.